AFFILIATIONS
1 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
2 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
3 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
4 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
5 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
6 Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
7 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Leukemia Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
8 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Leukemia Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
9 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Leukemia Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
10 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
11 Leukemia Tissue Bank, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Leukemia Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, Leukemia Tissue Bank, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
13 Ontario Institute for Cancer Research, Toronto, Canada
14 Molecular Genetics, University of Toronto, Toronto, Ontario, Canada, Ontario Institute for Cancer Research, Toronto, Canada
15 Department of Medicine, University of Toronto, Toronto, Ontario, Canada, Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
ABSTRACT
Background: Longitudinal next-generation sequencing (NGS) monitoring enables tracking of somatic mutations at diagnosis (Dx), pre-transplant (Pre) and post-transplant (Post) time-points relative to allogeneic hematopoietic cell transplantation (HCT). Whether mutation persistence predicts relapse may depend on the timepoint assessed and the biology of the somatic mutation. DTA mutations (i.e. DNMT3A, TET2, ASXL1) frequently persist as age-related clonal hematopoiesis (CH) and are prognostically neutral, potentially confounding molecular measurable residual disease (MRD) interpretation. We evaluated the timepoint- and gene-specific prognostic impact of mutation persistence in myeloid malignancies before and after allogeneic HCT with reference to mutation profile at the time of initial diagnosis.
Methods and patients: We studied patients with myeloid malignancies (AML, MDS, MPN; n=233) undergoing allo-HCT with serial NGS at Dx, Pre and day 60 post-HCT. We applied a bar-coded single-molecule molecular inversion probe (smMIP) panel for pre- and post-HCT samples; this overcomes high error rates by tracking all sequence reads from a single strand with a limit of detection up to 0.2%. The diagnostic molecular profile was referenced by our clinical NGS testing (Illumina TruSight). The panel includes 31 genes with 332 amplicon probes such as genes in epigenetic modifiers (n=7), activation signaling (n=10), myeloid transcription factor (TF; n=5), spliceosome (n=4), tumor suppressor (n=1), and cohesion (n=4). A variant allele frequency >0 was defined as “detection”. For each transition (Dx→Pre and Dx→Post), patients were classified as persistence (≥1 Dx mutation remaining detectable) or clearance (all Dx mutations cleared, merged with never-detected); newly emergent mutations (Dx-negative/timepoint-positive) were excluded from the analysis. Persistence was further split into DTA persistence (only DNMT3A/TET2/ASXL1 persisting) versus non-DTA persistence. Endpoints were overall survival (OS), relapse-free survival (RFS; Kaplan-Meier, log-rank) and cumulative incidence of relapse (CIR; competing-risk analysis against non-relapse mortality, cause-specific comparison), reported at 2 years. Median follow-up was 29 months; overall 2-year OS, RFS and CIR were 55%, 49% and 24%.
Results: For the Dx→Pre transition (n=79 evaluable; 5 emergent excluded), persistence was paradoxically associated with more favorable outcomes than clearance (2-yr CIR 25% vs 44%). Splitting persistence by gene resolved the paradox: DTA persistence (n=14) showed the best outcomes of all groups (2-yr OS 77%, RFS 62%, CIR 23%), whereas non-DTA persistence (n=35; OS 51%, RFS 46%) and clearance (n=30; OS 43%, RFS 36%, CIR 43%) showed worse but similar outcomes to each other (3-group OS p=0.32, RFS p=0.39). Pre-transplant persistence thus largely reflected benign DTA clonal hematopoiesis rather than residual disease, with DTA-CH carriers showing the most favorable post-transplant course. In contrast, for the Dx→Post transition (n=53 evaluable; persistence 15, clearance 38; 3 emergent excluded), persistence of any mutation into the post-transplant period conferred significantly worse outcomes: 2-yr RFS 29% vs 57% (p=0.015) and 2-yr CIR 50% vs 24% (p=0.023), with OS 34% vs 60% (p=0.10). The cause-specific hazard ratio for relapse was 2.96 (95% CI 1.12–7.83, p=0.029), i.e. an approximately 3-fold higher cumulative incidence of relapse. Post-transplant persistence therefore identified true residual disease surviving transplant.
Conclusion: In myeloid malignancies undergoing allogeneic HCT, the prognostic meaning of molecular persistence is time-point-dependent. Pre-transplant (Dx→Pre) persistence is dominated by benign DTA clonal hematopoiesis and appears protective, particularly with DTA persistence. Post-transplant (Dx→Post) persistence reflects genuine residual disease, translating into an approximately 3-fold higher risk of relapse (RFS p=0.015, CIR p=0.023). These data indicate that DTA-aware molecular MRD assessed prior to HCT is critical, given that DTA-persistence is benign with favorable outcomes, while non-DTA persistence provides clinically actionable signal and supports serial post-transplant NGS monitoring to guide pre-emptive intervention. Prospective validation is strongly warranted in a larger number of patients.